Table 3.
Synergism between BTK and EGFR inhibitors
| Ibrutinib | AVL-292 | RN486 | ||||
|---|---|---|---|---|---|---|
| Gefitinib | Erlotinib | Gefitinib | Erlotinib | Gefitinib | Erlotinib | |
| Calu-6 | 0.04 | 0.20 | 0.18 | 0.18 | 0.13 | 0.10 |
| SK-Lu-1 | 0.02 | 0.20 | 0.13 | 0.17 | 0.11 | 0.11 |
| NCI-H1975 | 0.01 | 0.01 | 0.74 | 0.26 | 0.34 | 0.17 |
| NCI-H2228 | 0.01 | ant | ant | ant | 0.18 | 0.11 |
Combination Index (CI) was calculated as reported by Fransson (Fransson, A., et al. (2016) J Ovarian Res 9 [1]: 27) and detailed in material and methods
0.8 < CI < 1.2 = additive effect, CI < 0.8 = synergistic effect (CI < 0.5 = strong synergistic effect), CI > 1.2 = sub-additive effect, ant = antagonistic effect